Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe
JAMA Dermatology · 2023
DOI: 10.1001/jamadermatol.2022.5991 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Margo J Reeder und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison. Hauptthemen laut MEDLINE: Dermatitis, Allergic Contact. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The common use of isothiazolinones as preservatives is a global cause of allergic contact dermatitis. Differences in allowable concentrations of methylisothiazolinone (MI) exist in Europe, Canada, and the US.
Objective
To compare the prevalence of positive patch test reactions to the methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) combination and MI alone in North America and Europe from 2009 to 2018. Design, Setting, and Participants This retrospective analysis of North American Contact Dermatitis Group, European Surveillance System on Contact Allergies (ESSCA), and the Information Network of Departments of Dermatology (IVDK) databases included data from patients presenting for patch testing at referral patch test clinics in North America and Europe. Exposures Patch tests to MCI/MI and MI. Main Outcomes and Measures Prevalence of allergic contact dermatitis to MCI/MI and MI.
Results
From 2009 to 2018, participating sites in North America and Europe patch tested a total of 226 161 individuals to MCI/MI and 118 779 to MI. In Europe, positivity to MCI/MI peaked during 2013 and 2014 at 7.6% (ESSCA) and 5.4% (IVDK) before decreasing to 4.4% (ESSCA) and 3.2% (IVDK) during 2017 and 2018. Positive reactions to MI were 5.5% (ESSCA) and 3.4% (IVDK) during 2017 and 2018. In North America, the frequency of positivity to MCI/MI increased steadily through the study period, reaching 10.8% for MCI/MI during 2017 and 2018. Positive reactions to MI were 15.0% during 2017 and 2018. Conclusions and Relevance The study results suggest that in contrast to the continued increase in North America, isothiazolinone allergy is decreasing in Europe. This trend may coincide with earlier and more stringent government regulation of MI in Europe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison.
- Department of Dermatology, Park Nicollet Health Services, Minneapolis, Minnesota.
- Department of Dermatology, University of Minnesota, Minneapolis.
- Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota.
- Department of Dermatology, Columbia University Irving Medical Center, New York, New York.
- Information Network of Departments of Dermatology, Institute at the University Medical Center Göttingen, Göttingen, Germany.
Zitieren
APA
Reeder, M. J., Warshaw, E., Aravamuthan, S., Belsito, D. V., Geier, J., Wilkinson, M., Atwater, A. R., White, I. R., Silverberg, J. I., Taylor, J. S., Fowler, J. F., Maibach, H. I., DeKoven, J. G., Buhl, T., Botto, N., Giménez-Arnau, A. M., Gallo, R., Mowad, C., Lang, C. C. V., …, & Uter, W. (2023). Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2022.5991
Vancouver
Reeder MJ, Warshaw E, Aravamuthan S, Belsito DV, Geier J, Wilkinson M, et al. Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2022.5991
BibTeX
@article{Reeder2023,
author = {Reeder, Margo J and Warshaw, Erin and Aravamuthan, Srikanth and Belsito, Donald V and Geier, Johannes and Wilkinson, Mark and Atwater, Amber Reck and White, Ian R and Silverberg, Jonathan I and Taylor, James S and Fowler, Joseph F and Maibach, Howard I and DeKoven, Joel G and Buhl, Timo and Botto, Nina and Giménez-Arnau, Ana Maria and Gallo, Rosella and Mowad, Christen and Lang, Claudia C V and DeLeo, Vincent A and Johnston, Graham and Pratt, Melanie D and Brockow, Knut and Adler, Brandon L and Houle, Marie-Claude and Dickel, Heinrich and Schuttelaar, Marie Louise A and Yu, JiaDe and Spiewak, Radoslaw and Dunnick, Cory and Filon, Francesca Larese and Valiukeviciene, Skaidra and Uter, Wolfgang},
title = {Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe},
journal = {JAMA Dermatology},
year = {2023},
doi = {10.1001/jamadermatol.2022.5991}
}
EUVIMED